{"id":1042039,"date":"2012-05-06T15:45:54","date_gmt":"2012-05-06T15:45:54","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/longevity-medicine\/michael-j-fox-foundation-grant-to-dr-samuel-young-will-provide-parkinsons-drug-development-tools.php"},"modified":"2024-08-17T16:53:56","modified_gmt":"2024-08-17T20:53:56","slug":"michael-j-fox-foundation-grant-to-dr-samuel-young-will-provide-parkinsons-drug-development-tools","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/longevity-medicine\/michael-j-fox-foundation-grant-to-dr-samuel-young-will-provide-parkinsons-drug-development-tools.php","title":{"rendered":"Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinson&#8217;s drug development tools"},"content":{"rendered":"<p><p>Public  release date: 3-May-2012  [ |   E-mail   |  Share    ]  <\/p>\n<p>    Contact: Dennis Tartaglia    <a href=\"mailto:dtartaglia@tartagliacommunications.com\">dtartaglia@tartagliacommunications.com<\/a>    732-545-1848    Tartaglia    Communications<\/p>\n<p>    Samuel M. Young, Jr., PhD, research group leader at the new Max    Planck Florida Institute (MPFI), has received his first grant    from The Michael J. Fox Foundation for Parkinson&#8217;s Research    (MJFF). The grant will enable Dr. Young and colleagues to    develop a technology that will help scientists working in drug    development to research potential treatments that target LRRK2,    a Parkinson&#8217;s-related gene. Globally, five million people have    Parkinson&#8217;s disease.  <\/p>\n<p>    &#8220;We are excited about receiving The Michael J. Fox Foundation    grant, as these grants are competitive and MJFF is the world&#8217;s    largest private funder of Parkinson&#8217;s research,&#8221; said Dr.    Young, who directs MPFI&#8217;s Molecular Mechanisms of Synaptic    Function research group. &#8220;We believe that the tools we develop    will prove important in advancing Parkinson&#8217;s research.&#8221;  <\/p>\n<p>    Translational researchers working in Parkinson&#8217;s disease have    been hindered in studying the function of the LRRK2 gene in    pre-clinical models of Parkinson&#8217;s. This has been due to    difficulty in expressing this gene with commonly used    neuroscience research tools known as recombinant viral vectors.    Dr. Young will develop tools that will allow researchers to get    around this problem.  <\/p>\n<p>    Mutations in the gene for leucine-rich repeat kinase 2 (LRRK2)    are among the most common genetic links to Parkinson&#8217;s disease    yet discovered. LRRK2 has garnered much excitement among drug    makers due to its reported protein kinase activity, which    appears to be enhanced by Parkinson&#8217;s disease-causing    mutations.  <\/p>\n<p>    &#8220;We are delighted that The Michael J. Fox Foundation has    awarded Dr. Young with a grant to lead this critical project,&#8221;    said David Fitzpatrick, PhD, CEO and Scientific Director of    MPFI. &#8220;This grant recognizes Dr. Young&#8217;s specialized expertise,    as well as our Institute&#8217;s leadership role in neural circuit    research.&#8221;  <\/p>\n<p>    Recombinant viral vectors are used by scientists to deliver    genetic material into cells. Viruses have evolved specialized    molecular mechanisms to efficiently transport their genomes    inside the cells they infect. To create the vector, viruses are    bioengineered to strip their viral genome or most of their    viral genome, which renders them harmless. This enables them to    carry transgene expression cassettes to express a gene of    interest. The transgene expression cassette is a fragment of    DNA that carries the regulatory elements necessary for cells to    express specific genes within a cell or organism.  <\/p>\n<p>    As the principal investigator of the project, Dr. Young will    work with collaborators at other institutions to generate the    optimal expression cassette to express LRRK2.  <\/p>\n<p>    Dr. Young has specialized training that makes him the ideal    investigator for this project. After training in virology and    in recombinant viral vectors during his doctoral studies, Dr.    Young switched fields and became a post-doctoral neuroscience    researcher, learning electrophysiology techniques. He carried    out a second post-doctoral position, gaining further experience    with advanced electrophysiological techniques as well as    calcium imaging. Using this unique training, which combines    techniques in molecular, electrophysiological and biophysical    methods, Dr. Young and his group at MPFI study the molecular    mechanisms regulating synaptic function. Understanding these    mechanisms is critical because the major causes of brain    diseases are due to synaptic dysfunction.  <\/p>\n<\/p>\n<p>See more here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.eurekalert.org\/pub_releases\/2012-05\/tc-mjf050212.php\" title=\"Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinson's drug development tools\" rel=\"noopener\">Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinson&#039;s drug development tools<\/a><\/p>\n<p>Source:<br \/><a href=\"http:\/\/www.longevitymedicine.tv\/feed\/\">http:\/\/www.longevitymedicine.tv\/feed\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Public release date: 3-May-2012 [ | E-mail | Share ] Contact: Dennis Tartaglia <a href=\"mailto:dtartaglia@tartagliacommunications.com\">dtartaglia@tartagliacommunications.com<\/a> 732-545-1848 Tartaglia Communications Samuel M. Young, Jr., PhD, research group leader at the new Max Planck Florida Institute (MPFI), has received his first grant from The &hellip; <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/longevity-medicine\/michael-j-fox-foundation-grant-to-dr-samuel-young-will-provide-parkinsons-drug-development-tools.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246678],"tags":[],"class_list":["post-1042039","post","type-post","status-publish","format-standard","hentry","category-longevity-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1042039"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1042039"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1042039\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1042039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1042039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1042039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}